In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute lymphoblastic leukemia who undergo allogeneic hematopoietic stem cell transplantation. Fifteen patients received fludarabine 30 mg/m 2 , cytarabine 2000 mg/m 2 , amsacrine 100 mg/m 2 on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 Â 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation. At the time of hematopoietic stem cell transplantation, 10 patients were in complete remission (8 CR1; 2 CR2), 3 with primary refractory and 2 suffered from refractory relapse. All patients achieved a complete remission after hematopoietic stem cell transplantation; and after a median follow-up time of 1091 days (range, 334-1554 days), nine patients (60%) are alive and free from disease, including three patients with prior refractory disease. Three patients died due to treatment-related mortality. The most frequent and severe conditioning-related toxicities observed in 9 out of 15 patients were grade III/IV infections according to common toxicity criteria. Thus, conditioning with the FLAMSA-ATG-TBI regimen is a feasible and effective alternative for patients with relapsed or high-risk acute lymphoblastic leukemia.
Introduction
The use of intensified conventional induction chemotherapies in the treatment of newly diagnosed ALL in adult patients has led to initial CR rates of up to 90%. But, as some patients are even refractory to first-line therapy, the majority of the responding patients unfortunately suffer from relapse. Therefore, the probability of long-term disease-free survival is o30%. [1] [2] [3] [4] [5] Risk stratification based on prognostic factors allows identification of high-risk ALL patients with poor prognosis. [6] [7] [8] [9] [10] [11] [12] Myeloablative conditioning therapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) is currently the treatment of choice for these high-risk patients. [13] [14] [15] A combination of cyclophosphamide (120 mg/kg) and total body irradiation (TBI, 12 Gy in six fractions) has been used as a standard myeloablative conditioning regimen in ALL patients for the last 30 years. 16 Recently, a combination of TBI and etoposide has been suggested to be superior for patients in CR2. 16, 17 But, despite the use of these myeloablative regimens followed by allogeneic HSCT, relapse has remained a significant cause of death in high-risk ALL patients. The introduction of intensified conditioning regimens, by additional use of VP-16, improved disease control, but was counterbalanced by higher rates of toxicity and treatment-related mortality (TRM) . When looking at current conventional salvage chemotherapy regimens like fludarabine-cytarabine-idarubicine (FLAG-IDA) or fludarabine-cytarabine-mitoxantrone (FLAM), it is notable that secondary CR rates of up to 85% can be achieved in relapsed ALL patients. [18] [19] [20] On the basis of these findings and the promising results of a similar regimen developed by Kolb and co-workers 21, 22 in patients with acute myeloid leukemia we carried out a prospective single center study to investigate the safety and efficacy of an intensified conditioning regimen consisting of fludarabine, cytarabine, amsacrine (FLAMSA) and anti-thymocyte globulin (ATG) as well as 12 Gy TBI called FLAMSA-ATG-TBI. This report describes our experience with the first 15 patients who had high-risk, primary-refractory or relapsed ALL and received FLAMSA-ATG-TBI as a preparatory regimen before allogeneic matched related or unrelated HSCT.
Patients and methods

Patients
All patients gave written informed consent and were treated prospectively within a protocol approved by our hospital according to the guidelines of the local ethical committee. Between October 2004 and February 2008, a total of 15 patients (male 12, female 3) were enrolled into this study (Table 1) .
Risk stratification was performed according to the criteria of the German Multicenter Study Group for Adult ALL (GMALL) in Frankfurt. 23, 24 Here, high-risk ALL is defined by late achievement of CR (4day 26 despite consecutive treatment) or for B-lineage a white blood count at diagnosis of 430 000/ml or a pro-B-ALL or detection of either t(4;11) or t (9;22) . In the case of T-lineage ALL, high risk is defined by immunophenotypes of an early or mature T-ALL. In addition, a complex aberrant karyotype, with X3 aberrations including at least one structural aberration, defines high risk in both lineages. According to the GMALL criteria, risk stage at the time of diagnosis was standard risk for 1 patient, high risk for 13 patients and very high risk (t(9;22) þ ) for 1 patient. As additional risk factor, we included non-responders with active disease who were primary refractory or had experienced relapse. Seven patients had B-precursor ALL (B-ALL: two pro-B, three pre-B and two common ALL) and eight had T-cell ALL (T-ALL: two thymic-T, four early-T and two mature-T). Diagnosis was based on cytology, immunophenotyping and cytogenetics. In total, 3 patients had one risk factor and the other 12 patients had several (median, 3; range, 2-5) risk factors. The reasons for high-risk stratification were: refractory disease during first-line induction therapy (n ¼ 6), early relapse within 6 months after diagnosis despite initial response (n ¼ 4), ALL subtype including early and mature T-ALL as well as pro-B-ALL (n ¼ 8), complex abnormal cytogenetics (43 aberrations including at least one structural aberration), but bcr-abl negative (n ¼ 5), t(9;22) positive ALL (n ¼ 1), t(4;11) positive ALL (n ¼ 1) and white blood count 430 000/ml at the time of diagnosis in the case of B-ALL (n ¼ 4, median 223 000/ml (range, 38 000-629.000/ml)) ( Table 2) .
Median patient age at the time of transplantation was 26 years (range, 18-54 years). In all, 12 patients received transplants (PBSC 10, BM 2) from matched unrelated donors (80%), and 3 patients were transplanted with PBSC from matched sibling donors. With regard to HLAphenotype, 10 patients had an identical donor matched at HLA-A, -B, -C, -Dq and -Dr alleles using high-resolution DNA typing, whereas 5 patients had a donor with a single allele mismatch (two HLA-C, two HLA-Dqb1, one HLADrb1). The median number of CD34 þ cells within the allografts was 8.2 Â 10 6 /kg body weight (BW) (range, 1.5 Â 10 6 -29.3 Â 10 6 /kg BW). All 15 patients received primary induction therapy according to the GMALL protocol of the German ALL study group in Frankfurt. 23, 25 After induction therapy, nine patients achieved CR, whereas six (40%) were refractory and, therefore, classified as induction failures. Of these six patients three (50%; unique patient number, UPN 6, 7, 15) achieved CR after consolidation I according to GMALL (high-dose methotrexate and high-dose Ara-C) or salvage treatment with nelarabine (ARA-G) and were classified as CR1 with induction failure (CR1/IF). The remaining three patients (UPN 3, 9, 10) were refractory despite GMALL consolidation I and received conditioning therapy with active disease.
Four patients (27%) experienced early relapse during first-or second-consolidation therapy. Two of these (UPN 4, 8) received fludarabine-cytarabine-idarubicine salvage therapy and achieved a second CR (CR2) before transplantation. The other two patients failed to achieve a second CR despite the use of several salvage chemotherapy regimens (UPN 1: CLAEG, relapse protocol according to the Rostock study group, Germany, ARA-G; UPN 12: 4 Â Vincristin/Dexamethason/Dasatinib) and were transplanted in refractory relapse. The remaining five patients (UPN 2, 5, 11, 13, 14) were scheduled for allogeneic PBSCT after the first consolidation cycle because of accumulated risk factors like: extramedullary disease manifestation (UPN 2), ALL subtype (UPN 2, 5, 11, 14), cytogenetics (UPN 11, 13, 14), white blood count at diagnosis of 430 000/ml (UPN 5, 11) and increasing minimal residual disease burden in a quantitative assessment of minimal residual disease ( UPN 13, 14) .
Overall, a median of three earlier chemotherapy courses (range, 3-10 courses) were administered before allogeneic HSCT. At the time of allogeneic transplantation, 3 patients (20%; UPN 3, 9, 10) were primary refractory, 2 patients (13%; UPN 1, 12) suffered from refractory relapse and 10 patients (67%) received their allografts in CR (8 CR1 (UPN 13 þ 14 were minimal residual disease positive), 2 CR2). In January 2009, surviving patients had a median follow-up of 1091 days (range, 334-1554 days). , amsacrine 400 mg/m 2 )), ATG-Fresenius ( 20 mg/kg BW on days -6, -5 and -4 (total-dose: 60 mg/kg BW)) and fractionated TBI (2 Â 2 Gy on days -3, -2 and -1 (total-dose: 12 Gy)). After TBI, unmodified granulocyte-colony stimulating factor mobilized PBSC (n ¼ 13) or unmodified bone marrow (n ¼ 2) was infused. Immunosuppression was started on day -1 with tacrolimus (trough levels: 10-15 ng/ml) twice daily. One hour after HSCT, mycophenolatmofetil (15 mg/kg BW) was administered three times a day.
In the absence of GvHD, mycophenolatmofetil administration was tapered beginning at day þ 28 till day þ 50. Tacrolimus administration was individualized depending on appearance of GvHD. In patients without any symptoms of GvHD, tacrolimus was tapered beginning on day þ 70 till day þ 100.
All patients received prophylactic ciprofloxacin and metronidazol for selective intestinal decontamination from the beginning of conditioning therapy until hematological reconstitution. Furthermore, prophylactic fluconazole 200 mg/day was administered from the day of stem cell infusion until discontinuation of immunosuppression. Antiviral prophylaxis adjusted on the results of surveillance cultures and CMV serologic status was also administered to all patients. Trimethoprim-sulphamethoxazole was used as prophylaxis against Pneumocystis jiroveci and given until reconstitution of T4-helper lymphocyte 4200 cells/ml after HSCT.
Quantitative chimerism analyzes were performed using short-tandem-repeat-based polymerase chain reaction techniques at regular intervals for every 4 weeks after allografting in peripheral blood and at day þ 28, þ 100 and þ 365 after transplantation in bone marrow.
GvHD grading and treatment
Diagnosis and clinical grading of acute and chronic GvHD were performed according to established criteria. 26, 27 Initial treatment consisted of prednisone (1-2 mg/kg BW/day, taper started after 14 d) and the administration of tacrolimus was resumed at full dosage. Mycophenolate mofetil has only been resumed to full dose in cases of acute GvHD within the first 50 days after HSCT. Steroidrefractory acute GvHD was treated with additional T-cell and TNF-a directed monoclonal antibodies such as basiliximab and infliximab.
Statistical methods
Treatment response, GvHD-onset and overall survival were calculated from the day of transplantation to respective event. Death of what cause ever was counted as an event in 
UPN ¼ unique patient number; ALL subtype ¼ includes pro-B, early and mature T; complex aberrant karyotype ¼ X3 aberrations including at least one structural aberration; achievement of CR 4d 26 ¼ late achievement of complete remission despite consecutive therapy 4day 26; WBC ¼ white blood count.
FLAMSA-TBI followed by allogeneic stem cell transplantation F Zohren et al case of overall survival. All time-to-event curves were estimated according to the method of Kaplan and Meier. The statistical analyzes were performed using SPSS statistical software.
Results
Engraftment and chimerism
Leukocyte engraftment was defined as the first of three consecutive days of peripheral white blood count 41000/ ml. Platelet engraftment was defined as the first of seven consecutive days with platelet counts of 450 000/ml. All patients were successfully engrafted and there was no case of late graft failure within our study. The time needed for white blood cell engraftment varied between 13 and 34 days (median 18 days), whereas platelet counts 420 000/ml were observed between 12 and 26 days (median 17 days) and 450 000/ml between 16 and 47 days (median 23 days). As the FLAMSA-ATG-TBI regimen requires 10 days of consecutive treatment, we were particularly interested in the duration of aplasia, defined as white blood count (o1000/ml), in comparison to engraftment. The median duration of aplasia was 20 days (range, 13-36 days). A complete donor chimerism was observed in all patients at day þ 28 after HSCT. Three patients with relapse showed a decrease of donor chimerism as a consequence of the expanding malignant cells.
Survival and disease response
All 15 patients achieved a complete hematological and cytogenetic remission after myeloablative conditioning and allogeneic HSCT. At a median follow-up time of 1091 days (range, 334-1554 days), nine patients (60%) are alive (Table 3; Figure 1 ).
All surviving patients were in CR without evidence of disease. Among these were three patients (UPN 1, 3, 10 ) who suffered from refractory disease and failed to attain a cytological remission and another patient (UPN 14) who did not achieve a molecular remission before transplantation. One patient suffering from bcr-abl positive common ALL (UPN 12) became minimal residual disease positive after transplantation and received a donor lymphocyte infusion and Dasatinib reinducing a complete molecular remission.
Still, six patients (40%) died after transplantation, three from relapse (UPN 4, 8, 11) and three from treatmentrelated complications (UPN 9, 12, 13). The relapsed patients died on days þ 121, þ 340 and þ 449 after transplantation. Out of these, only one (UPN 4) developed mild GvHD symptoms. All three patients who died from treatment-related complications suffered from grade III FLAMSA-TBI followed by allogeneic stem cell transplantation F Zohren et al acute and/or extensive chronic GvHD. UPN 9 and 13 had acute GvHD grades II-III with involvement of the skin, liver and gut and received escalated GvHD treatment. UPN 9 developed transplantation-associated thrombotic microangiopathy and the patient died at day þ 87 post transplantation from multiorgan failure. UPN 13 died from septicemia at day þ 207 after transplantation. Patient UPN 12, suffering from bcr-abl positive common ALL became minimal residual disease positive after transplantation and received donor lymphocytes and Dasatinib causing an extensive cGvHD with liver involvement and he died due to liver failure on day þ 410 after transplantation (Table 3) .
Acute GvHD
Acute GvHD grades I-III occurred in seven patients (47%) and grades II-III in six patients (40%). There was no case of grade IV acute GvHD (Table 3 ). The onset of acute GvHD was observed at days þ 20, þ 23, þ 28, þ 36, þ 39, þ 40 and þ 80 after transplantation (median day þ 36). At this time, all but one patient received full-dose tacrolimus and additional mycophenolate mofetil. Organs involved were skin (n ¼ 5), gut (n ¼ 4) and liver (n ¼ 3). Two patients with isolated grade II involvement of the skin received topical corticosteroids, whereas the other five patients, who had grades I-III involvement of gut and liver or skin, received systemic corticosteroids. One of these (UPN 7) required further treatment with basiliximab because of refractory acute GvHD. Four out of seven patients with acute GvHD are currently alive and free of disease. Three of them developed chronic GvHD (1 limited, 2 extensive). Two patients (UPN 9, 13) suffering from acute GvHD grades II-III died due to treatment-related complications. UPN 4 who suffered from acute and chronic GvHD relapsed after decay of GvHD symptoms and died at day þ 449 after transplantation (Table 3) .
Chronic GvHD
Thirteen patients were evaluable for chronic GvHD (cGvHD). Seven patients (54%) had cGvHD (three limited, four extensive). Five patients (UPN 1, 4, 7, 13, 14) had earlier episodes of acute GvHD, one patient (UPN 2) developed a de novo cGvHD limited disease and another patient (UPN 12) developed an extensive cGvHD after infusion of donor lymphocytes (5 Â 10 6 kg/BW). Another patient (UPN 7) suffering from extensive disease had lung involvement and developed bronchiolitis obliterans, which resolved after steroid therapy.
Four of seven patients suffering from cGvHD are currently alive and free of disease. In all patients with limited disease, GvHD symptoms resolved. In these patients, immunosuppressive therapy was stopped on days þ 175, þ 227 and þ 371. UPN 7, who suffered from extensive disease with lung involvement, is also currently free of GvHD symptoms and immunosupressive therapy was stopped on day þ 680. Patient UPN 14 still requires immunosuppressive therapy on day þ 411 due to extensive cGvHD (Table 3) .
Early toxicity
Early toxicities, appearing from day -10 up to þ 50 after transplantation, were graded using the National Cancer Institute-Common Toxicity Criteria 2.0. With 9 out of 15 patients developing grade III/IV infections during cytopenia, infectious complications were of capital importance. In detail, these were: gram-negative septicemia (n ¼ 2; UPN 3, 5), aspergillus pneumonia (n ¼ 4; UPN 1, 5, 8, 14) , bacterial pneumonia (n ¼ 1; UPN 9), hemorrhagic BK virus cystitis (n ¼ 2; UPN 7, 11) and external otitis (n ¼ 1; UPN 4). Two patients, UPN 5 and 9, required intensive care treatment due to therapy-related complications. Remarkably, both cases of hemorrhagic BK virus cystitis were successfully treated with palifermin, a human recombinant keratinocyte growth factor. 28 The remaining non-hematological complications within this group of patients were almost exclusively limited to gastrointestinal toxicities. Grade I mucositis was seen in four patients, grade II in four, grade III in five and grade IV in two. All patients required parenteral nutrition during hospitalization. Five patients (33%) had grade III/IV nausea and another five patients (33%) showed grade III/ IV diarrhea in the absence of intestinal GvHD.
One patient had severe acute peripheral neuropathy that was attributable to tacrolimus treatment. Slight and transient renal and hepatic toxicity was common, but almost limited to grades I and II. Reversible grade III/IV nephrotoxicity was seen in one patient with gram-negative septicemia during intensive care treatment (UPN 5). Two patients showed grade III/IV hepatic toxicity, both suffering from acute GvHD with liver involvement.
There was no case of venous occlusive disease. One patient suffering from aGvHD grades II-III developed transplantation-associated thrombotic microangiopathy as mentioned above (Table 4) . 
Discussion
It is well known that especially among patients suffering from high-risk ALL both in CR1 and in CR2 myeloablative allogeneic HSCT is able to improve disease-free survival. 29, 30 But the results of the LALA-94 trial also showed that relapse of the underlying disease remains the major cause of death for patients with ALL even after myeloablative conditioning with cyclophosphamide/TBI and allogeneic HSCT. In comparison with a 3-year TRM rate of 18% in this trial, the 3-year relapse and disease-free survival rates were only 34 and 47%, respectively, indicating high rates of disease recurrence in adult ALL patients even after allogeneic transplantation. 31 These survival rates are even worse when taking into account that patients within the LALA-94 trial were in first CR before allogeneic HSCT. Intensified conditioning regimens have already been used in high-risk adult ALL patients and resulted in higher rates of disease control, but this success was counterbalanced by an increased rate of toxicity and transplant-related mortality. However, intensification of conditioning therapy before allogeneic HSCT could still be a viable approach to improve outcome, especially in young adults suffering from high-risk ALL. The composition of the intensified conditioning regimens has been rather conservative in the past, adhering basically to the standard of cyclophosphamide/TBI with the additional use of VP-16 or Ara-C. 17, [31] [32] [33] [34] Here, we report on the first 15 patients with high-risk or refractory ALL who received allogeneic matched unrelated donor or matched sibling donor HSCT after myeloablative conditioning using a novel and more intensive conditioning regimen called FLAMSA-ATG-TBI. Our primary purpose was to evaluate practicability, safety and complication profile of this regimen as a myeloablative conditioning therapy. Our secondary goal was to evaluate the long-term anti-leukemic effect of this treatment. The keynote of this regimen was the combination of a novel salvage therapy based on high-dose cytarabine, fludarabine and amsacrine with full-dose TBI.
Conditioning was started using FLAMSA chemotherapy to achieve clearance of malignant cells before the myeloablative component of this conditioning regimen. In this context, it is worth noting that current conventional salvage chemotherapy regimens in the treatment of relapsed ALL are based on the combined administration of high-dose cytarabine and fludarabine and have proven strong potency resulting in secondary CR rates of up to 80%. [18] [19] [20] In addition, pharmacological studies in patients with chronic and ALL have shown a synergistic effect of fludarabine and cytarabine, when administered consecutively. This effect relates to the increase of intracellular concentration of active metabolites such as AraCTP. 35, 36 Moreover, Arlin et al. 37 showed that the combination of high-dose cytarabine and amsacrine (4'-(9-acridinylamino) methansulfon-m-anisidine) also leads to increased CR rates up to 75% in relapsed or refractory ALL patients.
Then, after this initial phase of FLAMSA chemotherapy, patients received consecutive ATG infusions for 3 days. Finally, a myeloablative dosage of 12 Gy fractionated TBI was administered 7 days after the beginning of chemotherapy. It was intended to achieve a remission before TBI to improve outcome, as the prognosis of ALL patients who fail to achieve CR before allogeneic HSCT is very poor. 38 After a median follow-up of 1091 days, 60% of our patients are alive and free from disease. The rate of TRM in our study was 20% and no patient died before engraftment. Time to leukocyte engraftment was 18 days (median, range, 13-34 days) and thereby comparable with other intensified conditioning regimens such as cyclophosphamide/TBI/ Ara-C 32 and cyclophosphamide/TBI/VP-16.
32,39,40
With 60% patients suffering from grade III/IV (6 III, 3 IV) infectious complications during aplasia, infections were the main risks for our patients within the early post transplant phase. But, there was no case of TRM due to infectious complications. Gastrointestinal toxicities like nausea/vomiting, mucositis and diarrhea evoked by this regimen were the most common side effects. Grades III-IV nausea/vomiting was seen in 33%, grades III-IV mucositis in 46% and grades III-IV diarrhea in 33%, which was higher than in earlier studies with cyclophosphamide/TBI/ Ara-C or cyclophosphamide/TBI/VP-16. 32, 39, 40 However, no patient required preventive intubation or experienced aspiration pneumonia. Life-threatening toxicities other than infections did not accumulate. It is noteworthy that despite the use of high-dose Ara-C in combination with TBI, there were no cases of respiratory complications. These results indicate that the FLAMSA-ATG-TBI regimen is sufficiently practicable and, therefore, comparable with other myeloablative conditioning regimens with regards to TRM, although higher rates of gastrointestinal toxicity occurred. As only two patients were older than 40 years, the regimen-related toxicity in older patients remains unevaluated.
It is worth mentioning that, although 5 patients failed to reach a cytological remission and 2 failed to reach a molecular remission before allogeneic transplantation, all 15 patients achieved a CR after conditioning therapy. Moreover, four out of these refractory patients are alive and free from disease including three long-term survivors (UPN 1 þ 1554, UPN 3 þ 1091, UPN 10 þ 819) . These data suggest that allogeneic transplantation after conditioning with FLAMSA-ATG-TBI is able to induce longterm remission in otherwise refractory patients. Three patients transplanted in our study relapsed (20%) and died. This result compares well with other conditioning regimens that have been used in the past, 31, 41 especially considering the unfavorable state of disease in our patients. a Not associated with GvHD.
FLAMSA-TBI followed by allogeneic stem cell transplantation F Zohren et al With 7 out of 15 patients developing an aGvHD (46%) and 7 out of 13 evaluable patients showing cGvHD (53%), the incidences of acute and chronic GvHD are comparable with other studies. 14, 42 Considering the GvHD rates of our patients transplanted with matched unrelated donors, it is noteworthy that only 5 out of 12 patients developed an aGvHD (41%) and 4 out of 10 evaluable patients developed a cGvHD (40%), indicating that allogeneic matched unrelated donor transplantation might also be a feasible treatment for patients with high-risk ALL even in first remission missing a sibling donor. Although patients with GvHD in our study had a better outcome than those without GvHD, undermining the presence of a graftversus-leukemia effect, eradication of residual disease by the conditioning regimen is the basic requirement for disease control in this group of patients. Although there has been evidence for a graft-versus-leukemia effect in ALL, [13] [14] [15] 29 the potency of this graft-versus-tumor effect may be less powerful than in myeloid malignancies. Therefore, a conditioning regimen has to be sufficiently intense to facilitate engraftment and to provide an interval of remission to establish immunological control of the underlying residual disease.
In summary, the FLAMSA-ATG-TBI regimen was well tolerated and was not associated with specific early or longterm regimen-related toxicities. Our data suggest that this sequential high-dose regimen is an effective therapy for patients with refractory or high-risk ALL representing a practicable alternative to conventional cyclophosphamide/ TBI conditioning therapy, especially for younger adults. We, therefore, suggest that the FLAMSA-ATG-TBI regimen should be evaluated prospectively in randomized trials.
